MEET OUR EXTERNAL ADVISORY BOARD
Douglas C. Bauer, MD is Professor of Medicine and Epidemiology & Biostatistics at the University of California, San Francisco. He also serves as Director of the UCSF Clinical and Translational K Scholars Program, and is an Executive Committee member for the San Francisco Coordinating Center. For over 10 years he was the Director of Research, UCSF Division of General Internal Medicine. Dr. Bauer is a practicing general internist and clinical epidemiologist with active NIH-funded clinical research projects in several areas of aging, osteoporosis, and thyroid research, including risk factors, diagnostic tests, biomarkers and treatments. He has authored or co-authored over 450 peer reviewed publications, is an Associate Editor for the Primer on Metabolic Bone Diseases and Disorders of Mineral Metabolism, the serves on the Editorial Board the Journal of Bone and Mineral Research. He is a standing member FDA Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC),) and recently completed a 4-year term as a standing member of the Neurologic, Aging and Musculoskeletal Epidemiology (NAME) NIH Study Section. He served as a Trustee for the National Osteoporosis Foundation from 2013 to 2018.
Mary Bouxsein is Professor of Orthopedic Surgery at Harvard Medical School and Director of the Center for Advanced Orthopedic Studies at Beth Israel Deaconess Medical Center. She is also a faculty member in the combined Harvard-MIT Health Sciences and Technology Program. Dr. Bouxsein received her PhD in Mechanical Engineering from Stanford University and completed postdoctoral training at Harvard Medical School. Her research focuses on understanding the biomechanical underpinnings of skeletal fragility and includes preclinical as well as clinical studies. She has published over 400 peer-reviewed articles and 40 book chapters and invited reviews. In addition, she has served as an Associate Editor of the Journal of Bone and Mineral Research and Board Member of the International Osteoporosis Foundation. She currently serves on the Council for the National Institute of Arthritis, Skin and Musculoskeletal Diseases at the National Institutes of Health and is the President-elect of the American Society for Bone and Mineral Research.
Professor Robin Daly holds the position of Chair in Exercise and Ageing, co-leads the Preventing and Managing Chronic Diseases research domain and is Head of the Musculoskeletal Health and Mobility group within the Institute for Physical Activity and Nutrition at Deakin University, Melbourne, Australia. His research focuses on conducting clinical and translational randomized controlled trials and implementation studies to understand how exercise and nutritional approaches can prevent and manage diseases, particularly osteoporosis, sarcopenia, falls and fractures. His work has led to the implementation of evidence‐based, community exercise programs and nutritional products to optimise musculoskeletal health and body composition. He created the ‘Osteo-cise: Strong Bones for Life’ community-based osteoporosis prevention exercise program, which received federal funding for implementation in Australia. He has played a key advisory role and co-authored position statements on various exercise and nutrition guidelines, including the ‘Building Healthy Bones Throughout Life’ position paper published in the Medical Journal of Australia, and position statements on vitamin D for adults and exercise for osteoporosis. He is ranked in the top 0.1% of scholars writing about Accidental Falls and Muscle Strength over the past 10 years, and in 2021 was ranked in the top 2% of cited researchers in the field of Endocrinology and Metabolism. He is immediate-Past President of the Australian and New Zealand Society for Sarcopenia and Frailty Research (ANZSSFR), a member of the medical and scientific advisory committee of Healthy Bones Australia, a board member of the International Federation of Musculoskeletal Research Societies (IFMRS) and a past (2014-19) council member of the Australian and New Zealand Society for Bone and Mineral Research (ANZBMS). He is also a Fellow of Sports Medicine Australia and the American Society for Bone and Mineral Research (ASBMR).
Kassim Javaid is an adult rheumatologist at the Oxford University Hospitals NHS trust and an Associate Professor in metabolic bone disease at the University of Oxford. He specializes in clinical and research of common and rare metabolic bone diseases. He is the clinical lead for Oxford Fracture Prevention Service and the national Fracture Liaison Service Audit for England and Wales run through the Royal College of Physicians. Internationally, he co-chairs the International Osteoporosis Foundation Capture the Fracture programme that has audited over 400 services globally. He is clinical lead for the Oxford Rare bone disease service for adults and the national 100,000 Genomes Clinical Interpretation partnership for musculoskeletal conditions. His research interests include epidemiology of musculoskeletal diseases with a focus on rare diseases of the bone, vitamin D and secondary fracture prevention.
Diane Lacaille is the Scientific Director of Arthritis Research Canada, and a Professor, Division of Rheumatology, Department of Medicine, at the University of British Columbia, in Vancouver. She is affiliated with Vancouver Hospital and Health Sciences Center and she has a rheumatology practice in Vancouver, BC. She holds the Mary Pack Chair in Rheumatology Research from UBC and The Arthritis Society of Canada. She completed medical school and internal medicine training at Mc Gill University in Montreal, and her Rheumatology training and a Master’s in Health Sciences, clinical epidemiology, at the University of British Columbia. Her research focuses on two areas: 1) Studying the impact of arthritis on employment and preventing work disability. To that effect, she has developed, and tested in a randomized controlled trial, Making-it-WorkTM, an online program helping people with arthritis deal with employment issues. 2) Evaluating the quality of health care services received by people with rheumatoid arthritis (RA), developing and testing interventions to improve quality of care, and conducting pharmaco-epidemiology studies, using administrative health data from a population-based cohort of RA for the province of BC. Her research has been supported by peer reviewed grants from the Canadian Institute for Health and Research, the Canadian Arthritis Network, The Arthritis Society of Canada and the Canadian Rheumatology Association. She was awarded the Distinguished Investigator Award from the Canadian Rheumatology Association in 2019, and the Queen Elizabeth II Diamond Jubilee medal in 2013 for her research contributions.
Parminder Raina is a Professor in the Department of Health Research Methods, Evidence, and Impact, Lead Principal Investigator of the Canadian Longitudinal Study on Aging (CLSA) and Scientific Director of the McMaster Institute for Research on Aging (MIRA). As well, he holds a Canada Research Chair in Geroscience and the Raymond and Margaret Labarge Chair in Research and Knowledge Application for Optimal Aging and is one of the founding members of the McMaster Optimal Aging Portal and the Ontario Research Coalition of Aging Institutes/Centres. He was also member of the National Seniors Council from 2018 – 2021. He specializes in the epidemiology of aging with emphasis on developing the interdisciplinary field of Geroscience to understand the processes of aging from cell to society. He has expertise in epidemiologic modeling, systematic review methodology, injury, and knowledge transfer.
Dr. Robyn Tamblyn is a Professor of Medicine, a James McGill Chair, and a Medical Scientist at the McGill University Health Centre. She is Scientific Director of the McGill Clinical and Health Informatics Research Group. She was appointed Scientific Director of the CIHR Institute of Health Services and Policy Research in 2011 and served in this position until her term ended in December 2018. In 2005 Dr. Tamblyn received the CHSRF KT award for research in improving medication use and in 2006 she received the ACFAS Bombardier award for innovation in the development of a drug management system. In 2014, she received the John P. Hubbard Award for outstanding achievement in the assessment of professional competency in health care and medical education and she was appointed to the Order of Canada. In 2015 she received the Outstanding Achievement Award in the evaluation of clinical competence for sustained excellence in Canadian health care and research from the Medical Council of Canada. Dr. Tamblyn was selected as the 2018 Justice Emmett Hall Laureate in recognition of her outstanding contributions to the health ideals extoled by Justice Hall and she was named the recipient of the 2018 Peggy Leatt Award in acknowledgement of her work in improving outcomes in Canada’s health care system. Recently, in 2019, she was elected as a Fellow to the Royal Society of Canada and she was appointed Director of the Division of Clinical Epidemiology at the McGill University Health Centre.
Dawn Richards, PhD, is an analytical chemist by training, having earned her PhD in 2000 from the University of Alberta, developing methods for bioanalytical separation analyses. She has worked in a variety of roles in the past 20 years ranging from being a bench scientist in biotech, to a project manager in academia, and to facilitating partnerships and commercial activities at a not-for-profit cancer institute. In 2006, she was diagnosed with rheumatoid arthritis, and has since also been diagnosed with osteoarthritis. In 2017, Dawn founded Five02 Labs Inc., so she could combine her scientific training and her passion to ensure patients inform research and healthcare. She helps people and organizations design and execute on their ‘patient engagement’ initiatives using leading practices and tailoring their approaches to meet their goals and their patient partners’ needs. Some of her current clients include Clinical Trials Ontario, the Canadian Institutes of Health Research’s Institute of Musculoskeletal Health and Arthritis, and the University Health Network. She has contributed to the literature and practice in patient engagement around compensation of patient partners, authorship with patient partners, recognizing patients as people with various skills and who lead fulfilling lives, and education around patient engagement in research. As a volunteer, Dawn is Vice President of the Canadian Arthritis Patient Alliance, has been invited to and is involved in a number of People Living with Arthritis/Rheumatism in Europe (PARE, of the European Alliance of Associations for Rheumatology) activities, and was a member of The BMJ’s Patient Advisory Panel and the first Patient Advisor of the Canadian Medical Association’s Wait Time Alliance.
